Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Minty

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 11, 2022
Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and EuropeDaniel R Morales, Anna Ostropolets, Lana Lai, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology. Retina|March 22, 2024
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network StudyCindy X Cai, Akihiko Nishimura, Mary G Bowring, et al.
Journal of the American Medical Informatics Association : JAMIA|February 24, 2023
Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational studyAnna Ostropolets, Yasser Albogami, Mitchell Conover, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Research Square|March 10, 2021
Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDISDaniel Prieto-Alhambra, Kristin Kostka, Talita Duarte-Salles, et al.
Clinical Epidemiology|March 29, 2022
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Talita Duarte-Salles, Albert Prats-Uribe, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 11, 2022
Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and EuropeDaniel R Morales, Anna Ostropolets, Lana Lai, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology. Retina|March 22, 2024
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network StudyCindy X Cai, Akihiko Nishimura, Mary G Bowring, et al.
Journal of the American Medical Informatics Association : JAMIA|February 24, 2023
Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational studyAnna Ostropolets, Yasser Albogami, Mitchell Conover, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Research Square|March 10, 2021
Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDISDaniel Prieto-Alhambra, Kristin Kostka, Talita Duarte-Salles, et al.
Clinical Epidemiology|March 29, 2022
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Talita Duarte-Salles, Albert Prats-Uribe, et al.
Pageof 3